Information  X 
Enter a valid email address

PureTech Health PLC (PRTC)

  Print      Mail a friend

Thursday 31 August, 2017

PureTech Health PLC

Total Voting Rights

RNS Number : 3471P
PureTech Health PLC
31 August 2017
 

31 August 2017

 

PureTech Health plc

Total Voting Rights and Share Capital - Month End Disclosure

 

Pursuant to DTR 5.6.1 of the Disclosure Guidance and Transparency Rules:

 

As at 31 August 2017 the issued share capital of PureTech Health plc comprised 237,429,696 Ordinary shares of one pence each. There were no shares held in treasury.

 

The total number of voting rights in PureTech Health plc is therefore 237,429,696.

 

This information may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules. 

 

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the immune, nervous, and gastro-intestinal systems by intervening early and addressing the underlying pathophysiology of disease. The Company is advancing a rich pipeline that includes two pivotal or registration studies expected to read out in 2017, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programmes. PureTech Health's growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts, who along with PureTech's experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Contact:


PureTech Health

FTI Consulting


Allison Mead Talbot

+1 617 651 3156

[email protected]

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRWGUMPRUPMGAU

a d v e r t i s e m e n t